A new drug discovery system allows scientists to specifically target members of an important family of enzymes, called phosphatases, which were previously considered mostly “undruggable”.
26 July, 2018
MedPharm Ltd., a leading provider of contract topical and transdermal product design and formulation development services, is pleased to introduce three new members to its Board of Directors.
26 July, 2018
Related intellectual property exclusively licensed to PureTech Health and being advanced as part of growing internal research and development division
25 July, 2018
Menlo Park, CA – July 24, 2018 –Transcriptic announced today that it has entered into a multi-year collaboration agreement with Eli Lilly and Company whereby Lilly will license the Transcriptic Common Lab Environment (TCLE) to enable on-demand drug discovery operations at its San Diego Biotechnology Center. The solution Transcriptic is developing for Lilly will allow researchers across the globe to remotely design, synthesize and screen investigational molecules at the Lilly Life Science Studio (L2S2).
25 July, 2018
EpiSwitch™ biomarkers have the potential to predict patient response to treatments with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1 EpiSwitch™ biomarkers have been shown to offer prognostic stratifications in lymphoma patients Data presented at the ASH Summit on Emerging Immunotherapies for Hematologic Diseases on 13 July 2018, in Washington DC
21 July, 2018
Scientists at the University of Birmingham, UK, are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).
20 July, 2018
The topic of this month’s newsletter from Drug Discovery Today is “Novel Targets”.
16 July, 2018
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division. When combined with Catalent’s existing industry-leading drug development and manufacturing capabilities in the U.S. and Europe, the acquisition of Juniper will expand and strengthen Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and will complement its integrated global clinical and commercial supply network.
14 July, 2018
Researchers from VIB, Leuven University and University Hospital Leuven studied thousands of healthy and cancerous lung cells to create the first comprehensive atlas of lung tumor cells. Their results reveal that tumors are much more complex than previously appreciated, distinguishing 52 different types of cells. This new information can be used to identify new research lines for treatment. The results of the study will be published in the leading journal Nature Medicine.
13 July, 2018
Cambridge (UK) tech start-up, Repositive, has introduced new features to its Cancer Models Platform, responding to feedback from the platform’s growing user base. The platform provides oncology researchers with a holistic, searchable, comparable view of existing cancer models, whilst providing Contract Research Organisations (CROs) - the providers of the cancer models - with a tool to market, manage and analyse their models.
12 July, 2018
Scientists from Philip Morris International (PMI) have presented details of a series of advanced techniques for the in vitro toxicological assessment of complex mixtures. For the scientific assessment of heated tobacco and e-cigarette aerosols, PMI has developed and tested methodologies using human cells grown in three-dimensional cultures, networks-based systems toxicological analysis, and organ-on-a-chip models combining cells from multiple human organs.
11 July, 2018